Foster Financial Freedom with λ finance

At Lambda, we are on a mission to revolutionize financial strategies and methodologies. We believe the financial industry relies on outdated practices, and we are here to change that.

Contact Us

Our Partner

Angular SymbolAngular
Google SymbolGoogle
Instagram SymbolInstagram
ChatGPT SymbolChatGPT
Python SymbolPython
TypeScript SymbolTypeScript
Docker SymbolDocker

Market Overview

Real-time market movers and shakers

Top Gainers

Top Losers

Most Actives

General News

View More

Stock News

View More
News

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of KBR

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In KBR To Contact Him Directly To Discuss Their Options If you suffered losses in KBR between May 6, 2025 and June 19, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 15, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against KBR, Inc. ("KBR" or the "Company") (NYSE: KBR) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

News

RAPT Therapeutics: Strong Promise In Immunology, Looking Like An Opportunity At These Prices

RAPT Therapeutics is upgraded to a 'Buy' due to promising pipeline progress and attractive valuation after a significant share price decline. Ozureprubart, RAPT's lead candidate, showed favorable phase 2 data in chronic spontaneous urticaria, with potential for less frequent dosing than competitors. RAPT's strong cash position, bolstered by a $250 million offering, provides operational runway, but future cash burn for pivotal trials remains a risk.

News

BioLargo, Inc. (BLGO) Q3 2025 Earnings Call Transcript

BioLargo, Inc. (OTCQX:BLGO) Q3 2025 Earnings Call November 14, 2025 4:30 PM EST Company Participants Dennis Calvert - Chairman, President & CEO Dennis Calvert - Chief Financial Officer Conference Call Participants Brian Loper Presentation Operator Good day, everyone. Welcome to the BioLargo Q3 Earnings Results Conference Call.

Crypto News

View More
News

Bitcoin Market Top May Be In As Analyst Shares 1,064-Day Bull Cycle Pattern – Details

In the last week, Bitcoin lost the $100,000 support zone, marking another drastic turn in an extensive correction phase. Since then, prices have traded as low as $94,700 as the premier cryptocurrency strives to find market stability.

News

Will Shiba Inu price rebound as burn rate surges and exchange reserves dip?

Shiba Inu price remained under pressure as the crypto market pulled back despite having some important fundamentals, such as the rising burn rate and falling exchange balances.

News

Solana Active Addresses Tumble Yet Bulls Still Cling To Optimism

Solana's active addresses have slumped to a 12-month low from their previous peak amid shifting user behaviour.

Forex News

View More
News

Gold (XAU/USD) Price Forecast: Triangle Formation Shows Trader Indecision – Will $4,000 Hold?

An unusual positive correlation between the yellow metal and equities is adding confusion about where capital rotates when these outflows occur.

News

XAU/USD: Gold Falls Sharply on Further Cooling of Fed Dec Rate Cut Expectations

Gold lost ground on Friday and fell over 3% following more hawkish tones from Fed policymakers that further dropped bets for December rate cut (below 50%, compared to 80% on Thursday and over 90% just a couple of days ago).

News

EUR/USD clings to 1.1600 despite weekly pullback on trimmed Fed Cut bets

EUR/USD clings to 1.1600 despite weekly pullback on trimmed Fed Cut bets